Blue Jet Healthcare Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The company's authorisation and allotment committee approved the opening of the issue on 6 July 2026.

The floor price of Rs 531.70 is at a discount of 5.64% to the scrip?s previous closing price of Rs 563.50 on the BSE.

The company may offer a discount of not more than 5% on the floor price so calculated for the issue. The issue price will be determined in consultation with the bookrunning lead managers appointed for the issue.

Blue Jet Healthcare is a speciality pharmaceutical and healthcare ingredient company and an end-to-end integrated Contract Development and Manufacturing Organisation (CDMO).

On a standalone basis, the company reported a net profit of Rs 64.34 crore in Q4 FY26, down 41.56% year-on-year (YoY) but up 60.17% quarter-on-quarter (QoQ). Revenue from operations declined 31.07% YoY to Rs 234.67 crore in Q4 FY26 due to negligible sales of one molecule in the PI vertical. However, revenue increased 21.96% QoQ from Rs 192.41 crore, driven by higher sales of advanced contrast media.

Powered by Capital Market - Live News

Blue Jet Healthcare announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 17 June 2026.

On a standalone basis, the company reported a net profit of Rs 64.34 crore in Q4 FY26, down 41.56% YoY but rising 60.17% QoQ.

Revenue from operations declined 31.07% YoY to Rs 234.67 crore in Q4 FY26 due to negligible sales of one molecule in the PI vertical. However, revenue increased 21.96% QoQ from Rs 192.41 crore driven by higher sales of advance contrast media.

The company said the YoY decline in revenue reflected timing-related order phasing in select PI accounts and customer-side inventory normalization. However, management maintained that underlying demand visibility remains strong and expects normalization in upcoming quarters.

Gross profit stood at Rs 132.5 crore in Q4 FY26, down 29.2% YoY but up 33% QoQ. Gross margin improved to 56.4% from 51.7% in Q3 FY26, supported by favourable product mix and higher sales of contrast media intermediates.

Profit before tax stood at Rs 87.15 crore in Q4 FY26, down 40.8% YoY while rising 62.05% QoQ.

EBITDA stood at Rs 71.3 crore in Q4 FY26, down 49.1% YoY but increasing 52% QoQ. EBITDA margin improved to 30.4% from 24.4% in Q3 FY26.

On the cost front, raw material costs declined 43.18% YoY to Rs 92.89 crore, while employee expenses increased 15.57% YoY to Rs 18.48 crore. Interest costs rose sharply to Rs 0.58 crore from Rs 0.03 crore a year ago, while depreciation expenses increased 30.51% YoY to Rs 6.46 crore.

For the full year FY26, net profit declined 18.8% YoY to Rs 247.82 crore, while revenue fell 8.03% YoY to Rs 947.32 crore. PBT for FY26 declined 18.12% YoY to Rs 332.51 crore.

EBITDA for FY26 stood at Rs 294.1 crore, down 22.1% YoY, while EBITDA margin moderated to 31% from 36.7% in FY25.

Net cash flow from operating activities improved sharply to Rs 334.14 crore in FY26 from Rs 45.76 crore in FY25.

The board recommended a final dividend of Rs 1.2 per equity share of the face value of Rs 2 each for the Financial Year ended 31 March 2026.

Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient company and an end-to-end integrated Contract Development and Manufacturing Organisation (CDMO).

Powered by Capital Market - Live News

Blue Jet Healthcare announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 1.2 per equity Share (i.e. 60%) , subject to the approval of the shareholders.